New chemo cocktail aims to fight childhood germ cell tumors that return

NCT ID NCT07662018

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how well a combination of four chemotherapy drugs (gemcitabine, docetaxel, melphalan, and carboplatin) followed by a stem cell transplant works in children and teens up to age 21 whose germ cell tumors have come back or not responded to treatment. Researchers will track side effects and treatment outcomes in about 30 participants. The goal is to gather information that could help improve care for this hard-to-treat cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
gemcitabine, docetaxel, melphalan, carboplatin
What this could lead to
If successful, this combination could offer a treatment option for children whose germ cell tumors have returned or not responded to standard therapy.
What could go wrong
This is an observational study with a small group of 30 participants, so results may not apply broadly. The chemotherapy regimen carries risks of serious side effects, including infection and organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARBOPLATIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.